within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EA01_Imatinib;

model Imatinib_1
  extends Pharmacolibrary.Drugs.ATC.L.L01EA01_1;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01EA01_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Imatinib is a tyrosine kinase inhibitor used as standard of care for chronic myeloid leukemia and gastrointestinal stromal tumors.</p><h4>Pharmacokinetics</h4><p>Alternative pharmacokinetic model in healthy volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Peng, B, et al., &amp; Schran, H (2005). Clinical pharmacokinetics of imatinib. <i>Clinical pharmacokinetics</i> 44(9) 879–894. DOI:<a href=\"https://doi.org/10.2165/00003088-200544090-00001\">10.2165/00003088-200544090-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16122278/\">https://pubmed.ncbi.nlm.nih.gov/16122278</a></p></li><li><p>Mueller-Schoell, A, et al., &amp; Kloft, C (2021). Therapeutic drug monitoring of oral targeted antineoplastic drugs. <i>European journal of clinical pharmacology</i> 77(4) 441–464. DOI:<a href=\"https://doi.org/10.1007/s00228-020-03014-8\">10.1007/s00228-020-03014-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33165648/\">https://pubmed.ncbi.nlm.nih.gov/33165648</a></p></li><li><p>Lyseng-Williamson, K, &amp; Jarvis, B (2001). Imatinib. <i>Drugs</i> 61(12) 1765–1776. DOI:<a href=\"https://doi.org/10.2165/00003495-200161120-00007\">10.2165/00003495-200161120-00007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11693465/\">https://pubmed.ncbi.nlm.nih.gov/11693465</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Imatinib_1;
